Nivolumab, an anti-programmed cell death-1 monoclonal antibody, has improved the survival of patients with malignant melanoma. Despite its efficacy, nivolumab inconsistently induces thyroid dysfunction as an i...
Authors:
Seiichi Yano, Kenji Ashida, Hiromi Nagata, Kenji Ohe, Naoko Wada, Yukina Takeichi, Yuki Hanada, Yuta Ibayashi, Lixiang Wang, Shohei Sakamoto, Ryuichi Sakamoto, Hiroshi Uchi, Motoaki Shiratsuchi, Masutaka Furue, Masatoshi Nomura and Yoshihiro Ogawa
Citation:
BMC Endocrine Disorders
2018
18:36
Content type: Research article
Published on: 8 June 2018